Trending Conversations at BIO-Europe

Biotech partnerships are evolving rapidly—shaped by increasing complexity, higher stakes, and the need for faster, more coordinated global execution.

At BIO-Europe Spring, Josh Hessing from Tanner Pharma connected with industry leaders to explore how these shifts are redefining decision-making across biopharma. This recap captures the key themes emerging from those conversations.

With over 2,000 companies represented, the discussions reflected a shared focus: how to evaluate opportunities more effectively, scale globally, and operationalize assets with confidence. Partnership success is no longer just about identifying the right asset, it is about enabling speed, alignment, and execution.

AI also featured prominently, not as a replacement for expertise, but as a tool to enhance it—supporting earlier risk identification, improving trial design, and enabling more informed business development strategies.

At the same time, momentum is building across key therapeutic areas, including oncology, rare diseases, metabolic conditions, and advanced therapies. Each bringing unique considerations for access, supply, and long-term delivery.

Supporting smarter global strategies

At Tanner Pharma, we help biopharmaceutical companies translate strategy into action—through reliable global access pathways and Clinical Trial Solutions that support execution at every stage.